Study of AZD0754 in Participants With Metastatic Prostate Cancer
← catalyst calendarNCT06267729 · readout in 97 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
60estimated
Sites
15
Countries
Australia, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-12 | actual | When the study began enrolling |
| Primary completion | 2026-11-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-24 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Prostate Cancer
Interventions
- Biological: AZD0754
- Biological: AZD2287
Primary outcome
what the primary-completion date above is the date OFIncidence of participants with Dose-limiting Toxicity (DLTs)/DLT-like events, Adverse Events (AEs), including Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs).
measured Through study completion, an average of 2 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed